Taltz ® (ixekizumab) injektion

För fullständig produktresumé för Taltz® se FASS.

Denna information är endast avsedd för sjukvårdspersonal verksam i Sverige och som svar på din fråga. Informationen nedan är på engelska

Taltz® ▼ (ixekizumab): Effekt på psoriasis i olika kroppsregioner

Patienter som fick ixekizumab hade signifikant förbättring av psoriasis på huvud/hals, bål, armar och ben så tidigt som vecka 1 jämfört med placebo.

Detailed Information

  • A post hoc analysis was performed to assess the efficacy of ixekizumab on psoriasis affecting the 4 anatomical regions (head/neck, trunk, arms, and legs) that comprise the PASI score.1

  • Mean percent improvements in PASI from baseline were significantly greater in patients receiving ixekizumab Q2W or Q4W compared to patients receiving placebo as early as week 1 and at every time point in all PASI body regions (p<.001 vs placebo) in the integrated analysis of the pivotal phase 3 trials, UNCOVER-1, -2, and -3.1

  • To compare the efficacy of ixekizumab to etanercept by body region, UNCOVER-2 and -3 data were pooled for post hoc analysis. In UNCOVER-2 and -3, a significantly greater proportion of patients receiving ixekizumab Q2W or Q4W achieved 75, 90, and 100% improvements in all regional PASI body assessments compared to patients receiving etanercept or placebo from weeks 1 or 2 and through to week 12.1  

  • As shown in Table 1, at week 12, the percentage of ixekizumab treated patients achieving 90 or 100% improvements was highest in the head/neck or trunk regions followed by the arms and legs. At week 12, 75% improvement was highest in the trunk and arms, though differences were minimal.1

  • Table 1 also includes week 60 data from UNCOVER-3 for patients receiving the recommended dosing regimen of ixekizumab Q2W through week 12 followed by ixekizumab Q4W. At week 60, numerical differences in response for different body regions were no longer apparent, except for the trunk region.1 

Table 1.  Regional PASI Responses at Week 12 (UNCOVER-2 and -3) and Week 60 (UNCOVER-3), NRI1


Week 12
UNCOVER-2 and -3 Pooled

Week 60
UNCOVER-3

PASI Body Region
PASI Outcome

PBO
N=361

ETN
N=740

IXEQ4W
N=733

IXEQ2W
N=736

IXEQ2W/IXEQ4W

Head/Neck

75% improvement

11.6

60.7a

76.8ab

83.8ab

82.0

90% improvement

7.8

48.8a

68.5ab

74.7ab

76.8

100% improvement

6.6

42.0a

62.8ab

68.6ab

74.6

Trunk

75% improvement

6.6

57.2a

81.6ab

87.9ab

87.0

90% improvement

3.0

38.9a

70.7ab

77.4ab

82.0

100% improvement

2.5

32.8a

61.9ab

67.4ab

80.4

Arms

75% improvement

6.9

49.2a

77.5ab

87.0ab

85.4

90% improvement

2.8

24.5a

60.7ab

67.1ab

74.3

100% improvement

1.7

17.6a

50.3ab

57.2ab

72.1

Legs

75% improvement

5.5

43.9a

78.3ab

84.4ab

88.4

90% improvement

1.7

20.0a

58.3ab

63.7ab

79.3

100% improvement

1.1

12.8a

45.8ab

50.8ab

75.7

Abbreviations: ETN = etanercept; IXEQ2W = ixekizumab every 2 weeks; IXEQ4W = ixekizumab every 4 weeks; NRI = non-responder imputation; PASI = Psoriasis Area and Severity Index; PBO = placebo.

a p<.05 vs PBO.

b p<.05 vs ETN.

The dosing schedule IXEQ4W during the first 12 weeks of treatment (induction phase) is not consistent with the approved dosing schedule for plaque psoriasis in the Taltz summary of product characteristics. Please refer to the Taltz summary of product characteristics for approved dosing. 2

Therapeutic Indication

Ixekizumab is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.2

References

1. Blauvelt A, Muram TM, See K, et al. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. J Dermatolog Treat. 2018;29(3):220-229. http://dx.doi.org/10.1080/09546634.2017.1365114

2. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Glossary

PASI = Psoriasis Area and Severity Index

Q2W = every 2 weeks

Q4W = every 4 weeks

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Datum fӧr senaste ӧversyn 2019 M04 19


Kontakta Medicinsk Information på Lilly

Kontakta oss på telefon

Kontorstid vardagar 9.00-17.00

Eller så kan du

Skriv din fråga till oss